259 related articles for article (PubMed ID: 30703077)
21. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
22. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
[TBL] [Abstract][Full Text] [Related]
23. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
24. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
[TBL] [Abstract][Full Text] [Related]
26. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
Curran D; Kim JH; Matthews S; Dessart C; Levin MJ; Oostvogels L; Riley ME; Schmader KE; Cunningham AL; McNeil SA; Schuind AE; Andrew MK;
J Am Geriatr Soc; 2021 Mar; 69(3):744-752. PubMed ID: 33197294
[TBL] [Abstract][Full Text] [Related]
27. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
[TBL] [Abstract][Full Text] [Related]
28. Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
Satyam VR; Li PH; Reich J; Qazi T; Noronha A; Wasan SK; Farraye FA
Dig Dis Sci; 2020 Oct; 65(10):2986-2991. PubMed ID: 31897892
[TBL] [Abstract][Full Text] [Related]
29. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
Dagnew AF; Klein NP; Hervé C; Kalema G; Di Paolo E; Peterson J; Salaun B; Schuind A
J Infect Dis; 2021 Oct; 224(7):1139-1146. PubMed ID: 32103273
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.
Xia Y; Zhang X; Zhang L; Fu C
Front Immunol; 2022; 13():978203. PubMed ID: 36248796
[TBL] [Abstract][Full Text] [Related]
31. Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia.
Muttucumaru R; Lau CL; Leeb A; Mills DJ; Wood N; Furuya-Kanamori L
Vaccine; 2024 May; 42(13):3166-3171. PubMed ID: 38677792
[TBL] [Abstract][Full Text] [Related]
32. Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
Ali SO; Dessart C; Parikh R
Vaccine; 2024 Mar; 42(8):2026-2035. PubMed ID: 38423814
[TBL] [Abstract][Full Text] [Related]
33. Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
Schmader KE; Levin MJ; Chen M; Matthews S; Riley ME; Woo W; Hervé C; Grupping K; Schuind AE; Oostvogels L; Curran D
J Gerontol A Biol Sci Med Sci; 2021 Feb; 76(3):485-490. PubMed ID: 32530462
[TBL] [Abstract][Full Text] [Related]
34. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
35. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA
Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682
[TBL] [Abstract][Full Text] [Related]
36. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
Haber P; Arana J; Pilishvili T; Lewis P; Moro PL; Cano M
Vaccine; 2016 Dec; 34(50):6330-6334. PubMed ID: 27836437
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.
Vink P; Delgado Mingorance I; Maximiano Alonso C; Rubio-Viqueira B; Jung KH; Rodriguez Moreno JF; Grande E; Marrupe Gonzalez D; Lowndes S; Puente J; Kristeleit H; Farrugia D; McNeil SA; Campora L; Di Paolo E; El Idrissi M; Godeaux O; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
Cancer; 2019 Apr; 125(8):1301-1312. PubMed ID: 30707761
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
Parikh R; Singer D; Chmielewski-Yee E; Dessart C
Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
